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Objectives: Data regarding the impact of breast cancer treatment-related neuropathic pain (NP) on sleep
quality are scarce. Therefore, we aimed to assess the impact of breast cancer treatment-related NP on
patients' sleep quality, during the first year after cancer diagnosis.
Materials and methods: A total of 501 breast cancer patients were followed prospectively. Incident NP
was identified through systematic evaluations after treatments and one year after enrolment. NP severity
was quantified using the Brief Pain Inventory severity subscale and sleep quality was evaluated through
the Pittsburgh Sleep Quality Index (PSQI), at baseline and after one year. Adjusted regression coefficients
(b) and 95% confidence intervals (95%CI) were used to quantify the relation between NP and the variation
in the PSQI z-scores.
Results: The occurrence of NP was associated with a deterioration in sleep quality during the first year of
follow-up, more pronounced among those with good sleep quality (PSQI5) than those with poor sleep
quality at baseline (PSQI>5) (b ¼ 0.44, 95%CI: 0.11 to 0.77 versus b ¼ 0.33, 95%CI: 0.08 to 0.59). These
differences were accentuated when only the cases of NP with greater severity were considered (b ¼ 0.86,
95%CI: 0.37 to 1.35 versus b ¼ 0.31, 95%CI: 0.08 to 0.64). Within the PSQI components, daytime
dysfunction and sleep duration were the most impaired by NP.
Conclusion: Our findings highlight the importance of the promotion of sleep hygiene among breast
cancer patients diagnosed with NP, especially among those with good sleep quality before treatments.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Neuropathic pain is defined, by the International Association for
the Study of Pain (IASP), as “pain arising as a direct consequence of
a lesion or disease affecting the somatosensory system” [1]. Among
breast cancer patients, it may occur due to: (a) cancer, when
resulting from the compression or infiltration of the central or
peripheral nervous system [2]; (b) comorbid conditions, such as
diabetic neuropathy or postherpetic neuralgia; (c) cancer treat-
ment, as a consequence of intraoperative damage to nervous sys-
tem structures [3] or following radiotherapy and chemotherapy [4].
The increase in the number of women diagnosed at earlier stages ofda Saúde Pública e Forenses e
de do Porto, Al. Prof Herna^nidisease and surviving for longer periods [5] highlights the impor-
tance of understanding the burden of cancer treatment-related
neuropathic pain and the assessment of its impact on patient-
reported outcomes, including health-related quality of life
(HRQOL) and specific dimensions of this broad construct.
Sleep disturbances have been shown to be an important
contributor to poor HRQOL [6,7] and are estimated to affect up to
two thirds of breast cancer patients [6,8e10]. In addition to factors
that increase the susceptibility to develop sleep disturbances and to
those that contribute to their maintenance over time, side effects of
breast cancer treatments are described to act as precipitating fac-
tors that may prompt their development among breast cancer pa-
tients [11]. Previous studies have shown that pain following cancer
treatments was associated with poorer sleep quality in breast
cancer patients [12e14]. However, data regarding the specific
impact of breast cancer treatment-related neuropathic pain on
sleep quality are scarce, and did not take into account the sleep
F. Fontes et al. / The Breast 33 (2017) 125e131126quality of the patients prior to treatments. In fact, in a high pro-
portion of women, sleep disturbances are already present before
treatment onset [15,16], whereas in others, sleep problems begin
months after cancer diagnosis [17], which emphasizes the need to
take into consideration baseline sleep quality status when assess-
ing the impact of neuropathic pain on this outcome.
Studies providing a comprehensive characterization of the
impact of cancer treatment-related neuropathic pain on patient
reports of sleep quality will contribute to a better characterization
of the burden associated with breast cancer treatments and may
contribute to the development of strategies to minimize the impact
of this condition, during treatment and in the long-term. We pre-
viously followed a cohort of breast cancer patients during one year
after cancer diagnosis showing that neuropathic pain was the most
frequent neurological complication during this period [18]. Now,
we aimed to assess the impact of breast cancer treatment-related
neuropathic pain on patients' sleep quality, in the same cohort of
women evaluated before treatment and followed during one year
after cancer diagnosis.2. Methods
This is a prospective cohort study with a one year follow-up
(Fig. 1). The study protocol has been described in detail elsewhere
[19]. Briefly, we consecutively selected women with newly diag-
nosed breast cancer, admitted to the Breast Clinic of the Portuguese
Institute of Oncology of Porto, Portugal, proposed for surgery, either
as primary treatment or after neoadjuvant chemotherapy, and not
having received any treatment for breast cancer before. We
excluded those treated with chemotherapy and/or radiotherapy in
the chest or axillary areas for other primary cancers and those with
a high probability of cognitive impairment (scores less than 17, or
less than 16 for women over 65 years old, in the Montreal Cognitive
Assessment [20]). From thosewho underwent a baseline evaluation
before treatment (N¼ 506), a total of 503 were followed during one
year (one patient died and two patients abandoned the study).
Sociodemographic data were collected at baseline using a
structured questionnaire applied by trained interviewers. Cancer
stagewas retrieved from clinical records after surgery and classifiedFig. 1. Study design and timing of baseline and follow-up evaluations. a 34 (11.4%) pa
chemotherapy.according to the American Joint Committee on Cancer seventh
edition cancer staging manual [21]. Data on breast cancer treat-
ments were obtained from the re-evaluation of clinical records one
year after enrolment.
Patients with incident cancer treatment-related neuropathic
pain were identified during systematic neurological evaluations
performed after surgery, after chemotherapy (when applicable)
and one year after enrolment, or through referral by anymember of
the clinical team (Fig. 1). Patients were considered to have neuro-
pathic pain when it was present in the previous 24 h, in the breast,
chest wall, axilla, or medial upper arm on the affected side, donor
region of breast reconstruction, or in the hands/feet (secondary to
chemotherapy-induced peripheral neuropathy). The grading sys-
tem adopted by the IASP was used to classify neuropathic pain as
“possible”, when pain distribution is neuroanatomically plausible
and history is suggestive of relevant lesions or diseases affecting the
somatosensory system, “probable”, when, in addition, the neuro-
logical examination confirms the presence of negative or positive
sensory signs, confined to the innervation territory of the injury
nervous structure, or a lesion or disease of the somatosensory
system is confirmed by diagnostic tests (e.g., neurophysiological
tests), or “definite”, when both the previous criteria are satisfied
[22]. In the present study, neuropathic pain was diagnosed using
only clinical history and clinical evaluationwithout complementary
exams. Pain sensation was assessed with a wood cocktail-stick and
light touch sensation by a piece of cotton wool, as recommend by
the IASP [22].
The severity subscale of the Brief Pain Inventory was used to
quantify pain severity in the previous 24 h [23]; it consists of a
mean score of four questions measuring the “worst”, “least”,
“average” and “current” pain (range: 0 to 10, with 0 corresponding
to ”no pain” and 10 to ”pain as bad as you can imagine”) [23]. The
pharmacologic management of neuropathic pain was assessed
through patients' self-report as well as data collected from clinical
files, regarding drugs prescribed to be taken on a daily basis.
The Hospital Anxiety and Depression Scale (HADS) was used to
evaluate anxiety and depression at baseline [24]. HADS consists of
14 items, with two 7-item subscales assessing anxiety and
depression in the previous week (range: 0 to 21 for each subscale);tients performed neoadjuvant chemotherapy and 263 (88.6%) performed adjuvant
Table 1
Sociodemographic and clinical characteristics of the patients (N ¼ 501).
N (%)
Age at baseline (years)
55 265 (52.9)
>55 236 (47.1)
Education at baseline (years)
4 215 (42.9)
5e9 142 (28.3)
10 144 (28.7)
Anxiety at baselinea 190 (37.9)
Depression at baselineb 41 (8.2)
Poor sleep quality at baselinec 302 (60.3)
Cancer stage
0 (DCIS) 34 (6.8)
I 234 (46.7)
II 155 (30.9)
III 75 (15.0)
IV 3 (0.6)
Breast surgery
None/Breast-conservingd 250 (49.9)
Mastectomy 251 (50.1)
Axillary surgerye
None/SLNB 329 (65.7)
ALND 172 (34.3)
Chemotherapyf 297 (59.3)
Radiotherapy (internal and/or external) 369 (73.6)
ALND, Axillary lymph node dissection; DCIS, Ductal carcinoma in situ; SLNB, Sentinel
lymph node biopsy.
a Defined as a score 11 in the anxiety subscale of the Hospital Anxiety and
Depression Scale.
b Defined as a score 11 in the depression subscale of the Hospital Anxiety and
Depression Scale.
c Defined as a score >5 in the Pittsburgh Sleep Quality Index.
d Patients who had both mastectomy and breast-conserving surgery are reported
as mastectomy; one patient only performed axillary surgery.
e Patients who had both ALND and SLNB are reported as ALND.
f Concomitant 5-fluorouracil, epirubicin and cyclophosphamide, followed by
docetaxel (N ¼ 176); concomitant doxorubicin and cyclophosphamide (N ¼ 60);
concomitant doxorubicin and cyclophosphamide, followed by docetaxel (N ¼ 32);
concomitant 5-fluorouracil, epirubicin and cyclophosphamide (N ¼ 24); concomi-
tant cyclophosphamide and docetaxel (N ¼ 2); concomitant 5-fluorouracil, cyclo-
phosphamide and methotrexate (N ¼ 1); concomitant carboplatin and docetaxel
(N ¼ 1); concomitant doxorubicin and cyclophosphamide, followed by paclitaxel
(N ¼ 1).
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to be indicative of clinically significant anxiety and/or depression,
as applicable [24].
The Pittsburgh Sleep Quality Index (PSQI) was used to evaluate
sleep quality at baseline and at one year [25]. The PSQI includes 19
items measuring seven components, including subjective sleep
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleep medication and daytime dysfunction. All
of the components (range: 0 to 3) are summed to provide a global
score designed to measured sleep quality over the past month
(range: 0 to 21); a score greater than five indicates poor sleep
quality [25].
2.1. Statistical analysis
A total of 501 participants were included in the present study,
after exclusion of those with missing information on sleep quality
(N ¼ 1) and anxiety or depression (N ¼ 1).
Sample characteristics are presented as counts and proportions
for categorical variables, and medians and percentiles 25 (P25) and
75 (P75) for quantitative variables. For analysis, age was catego-
rized, using the mean of the distribution among all participants as
the cutoff (55 years and >55 years), education was categorized as
four years or less (primary education), five to nine years (lower
secondary school) and 10 years or more (upper secondary and post-
secondary education), and cancer stage was categorized as cancer
stage 0 (Ductal carcinoma in situ) and I, II, and III and IV.
The Mann-Whitney U test was used to compare the variation of
the PSQI score during the first year after breast cancer diagnosis,
according to the occurrence of neuropathic pain. The improvement
and deterioration in sleep quality were defined as a decrease or an
increase of at least one point in the PSQI score, respectively.
Regression coefficients (b) and the corresponding 95% confi-
dence intervals (95%CI) were used to quantify the association be-
tween incident neuropathic pain and the variation in the PSQI
global z-score, during the first year after breast cancer diagnosis.
Results were stratified by the sleep quality status of the patients at
baseline and adjusted for potential confounders. Confounders were
selected among those known to be associated with both the
exposure and the outcome, but influenced by neither, according to
previous studies or expert knowledge, as described in the footnotes
of the corresponding table or figure. Similar models were fitted for
change in each of the PSQI components between baseline and the
one year follow-up evaluation. All analyses were stratified ac-
cording to sleep quality at baseline (PSQI 5 versus PSQI >5, cor-
responding to good and poor sleep quality, respectively).
Statistical analysis was conducted using STATA®, version 11.2
(StataCorp, College Station, TX, USA).
2.2. Ethics
The study was approved by the Ethics Committee of the Por-
tuguese Institute of Oncology of Porto (Ref. CES 406/011) and by the
Portuguese Data Protection Authority (Ref. 9469/2012). All partic-
ipants provided written informed consent.
3. Results
The sociodemographic and clinical characteristics of the pa-
tients are presented in Table 1. Half of the women had less than 55
years of age and almost half had less than four years of education.
Less than 10% were diagnosed with ductal carcinoma in situ and
around two thirds with cancer stage I or II. Nearly half were sub-
mitted to breast-conserving surgery. At baseline, 8.2% and 37.9% of
the participants had an HADS score indicative of clinical significantdepression and anxiety, respectively, and a total of 60.3% had poor
sleep quality, according to the PSQI.
During the first year of follow-up, a total of 156 patients were
diagnosed with neuropathic pain a median time (P25; P75) of 62.5
(35.5; 229.5) days after the baseline evaluation and 308.0 (131.0;
331.5) days before the one year follow-up. All cases were classified
as “probable” according to the IASP grading system. The median
scores (P25; P75) for pain severity and for worst pain intensity in
the last 24 h, at themoment of diagnosis, was 2.5 (1.5; 3.8) and 4 (3;
5), respectively. A total of 55 patients (35.3%) underwent pharma-
cological treatment for neuropathic pain until the one year follow-
up evaluation; the most frequent prescriptions were gabapentin
(81.8%) and pregabalin (32.7%). The prescription of treatment for NP
occurred more frequent in those with poor sleep quality than in
those with good sleep quality at baseline (14.8% and 5.0%, respec-
tively). A total of 3.2% of the patients had symptoms in the hands/
feet, corresponding to patients with chemotherapy-induced pe-
ripheral neuropathic pain.
The PSQI score variation during the first year after breast cancer
diagnosis, according to the occurrence of neuropathic pain and
sleep quality at baseline, is depicted in Fig. 2. Among patients with
good sleep quality at baseline, there was a deterioration in sleep
quality, significantly higher in those with neuropathic pain during
the first year of follow-up [median variation (P25; P75): 2 (0; 4)
Fig. 2. Variation of the Pittsburgh Sleep Quality Index (PSQI) score during the first year after breast cancer diagnosis, according to the occurrence of neuropathic pain (NP) and sleep
quality at baseline. NP, Neuropathic pain; PSQI, Pittsburgh Sleep Quality Index. a Defined as a score 5 in the PSQI. b Defined as a score >5 in the PSQI.
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at baseline, therewas an improvement in sleep quality until the one
year follow-up evaluation, significantly lower in those with
neuropathic pain during the first year of follow-up [median varia-
tion (P25; P75): 0.5 (2; 2.5) versus 1 (4; 2); p ¼ 0.030].
In the multivariable analysis, when considering all participants,
the occurrence of neuropathic pain was associated with a deterio-
ration in sleep quality during the first year of follow-up (variation in
the PSQI global z-score: b ¼ 0.32, 95%CI: 0.12 to 0.52) (Table 2).
However, this worsening was more pronounced among those with
good sleep quality than in those with poor sleep quality at baseline
(b ¼ 0.44, 95%CI: 0.11 to 0.77 versus b ¼ 0.33, 95%CI: 0.08 to 0.59).
These differences were accentuated when only neuropathic pain
with greater severity at themoment of its diagnosis was considered
(b ¼ 0.86, 95%CI: 0.37 to 1.35 versus b ¼ 0.31, 95%CI: 0.08 to 0.64).
When considering each of the PSQI components, among those
with good sleep quality at baseline, the incidence of neuropathic
pain was associated with a tendency for a deterioration in all
components during the follow-up, statistically significant only for
daytime dysfunction (b ¼ 0.52, 95%CI: 0.18 to 0.86) (Fig. 3A).Table 2
Regression coefficients (b) and the corresponding 95% confidence intervals (95%CI) for the
Sleep Quality Index (PSQI) global z-score in the first year after breast cancer diagnosisa,
All participants Good slee
Crude b (95%CI) Adjusted b (95%CI)d Crude b (9
NP incidence
Without NP 0 (ref.) 0 (ref.) 0 (ref.)
With NP 0.22 (0.03 to 0.41) 0.32 (0.12 to 0.52) 0.29 (0.0
Severity of NPe
Without NP 0 (ref.) 0 (ref.) 0 (ref.)
Severity  than median 0.22 (0.02 to 0.46) 0.28 (0.04 to 0.53) 0.11 (0.2
Severity > than median 0.19 (0.07 to 0.45) 0.33 (0.05 to 0.60) 0.64 (0.14
PSQI, Pittsburgh Sleep Quality Index; 95%CI, 95% Confidence intervals.
a Scores higher than zero correspond to a worsening of sleep quality during the follow
b Defined as a score 5 in the PSQI.
c Defined as a score >5 in the PSQI.
d Adjusted for age, education, cancer stage, anxiety and depression at baseline, breast
e Assessed through the severity subscale of the Brief Pain Inventory. The median valuHowever, there was also a statistically significant lower sleep
duration (b ¼ 0.70, 95%CI: 0.20 to 1.21) and more frequent use of
sleep medication (b ¼ 0.58, 95%CI: 0.06 to 1.09) when greater
neuropathic pain severity at the moment of its diagnosis was
analyzed (Fig. 3B).
Among those with poor sleep quality, the tendency for a dete-
rioration in each PSQI component was less consistent but there was
a statistically significant lower sleep duration (b ¼ 0.36, 95%CI: 0.10
to 0.62) and higher daytime dysfunction (b ¼ 0.32, 95%CI: 0.07 to
0.58) among those with incident neuropathic pain (Fig. 3A).4. Discussion
Our study provides a comprehensive characterization of the
impact of treatment-related neuropathic pain on patients' sleep
quality, one year after breast cancer diagnosis. The occurrence of
neuropathic pain was associated with deterioration in global sleep
quality, more pronounced among those with good sleep quality
prior to cancer treatments, with a greatest impact in daytime
dysfunction and sleep duration.relation between incident neuropathic pain (NP) and the variation of the Pittsburgh
according to sleep quality at baseline.
p quality at baselineb Poor sleep quality at baselinec
5%CI) Adjusted b (95%CI)d Crude b (95%CI) Adjusted b (95%CI)d
0 (ref.) 0 (ref.) 0 (ref.)
2 to 0.61) 0.44 (0.11 to 0.77) 0.30 (0.06 to 0.54) 0.33 (0.08 to 0.59)
0 (ref.) 0 (ref.) 0 (ref.)
6 to 0.48) 0.21 (0.18 to 0.59) 0.31 (0.00 to 0.62) 0.31 (0.02 to 0.63)
to 1.14) 0.86 (0.37 to 1.35) 0.24 (0.06 to 0.55) 0.31 (0.08 to 0.64)
-up.
and axillary surgery, chemotherapy and radiotherapy.
e of pain severity in those diagnosed with NP (2.5 out of 10) was used as cut-off.
Fig. 3. Regression coefficients (b) and the corresponding 95% confidence intervals (95%CI) for the relation between incidence of neuropathic pain (NP) (A) or incidence of NP with
greater severity (B) and the variation of the Pittsburgh Sleep Quality Index (PSQI) components z-scores in the first year after breast cancer diagnosis a, according to sleep quality at
baseline. NP, neuropathic pain; PSQI, Pittsburgh Sleep Quality Index; 95%CI, 95% confidence intervals. a Scores higher than zero correspond to a deterioration in each of the PSQI
components during the follow-up, e.g.worse subjective sleep quality, greater sleep latency, less sleep duration, less habitual sleep efficiency, greater sleep disturbance, greater use of
sleep medication and greater daytime dysfunction, as applicable. All values were adjusted for age, education, cancer stage, anxiety and depression at baseline, breast and axillary
surgery, chemotherapy and radiotherapy. b Defined as a score 5 in the PSQI. c Defined as a score >5 in the PSQI. d Severity assessed through the severity subscale of the Brief Pain
Inventory. The median value of pain severity in those diagnosed with NP (2.5 out of 10) was used as cut-off.
F. Fontes et al. / The Breast 33 (2017) 125e131 129Few previous studies have addressed the relation between
treatment-related neuropathic pain and sleep quality of breast
cancer patients [26,27]. In a study from Israel, assessing the rela-
tionship between symptom clusters and chemotherapy-induced
neuropathic pain in a sample of 40 patients treated with pacli-
taxel, the authors found that the “high cluster group” includedpatients who reported both high levels of pain with neuropathic
pain characteristics and sleep disturbances [26]. A study from Spain
assessing patients for a median time of 18 months after cancer
diagnosis, found that the pharmacological treatment of neuro-
pathic pain was associated with an improvement in sleep quality
eight weeks later [27]. In both studies, the identification of
F. Fontes et al. / The Breast 33 (2017) 125e131130neuropathic pain was based on a screening instrument, estimated
to fail to detect 10% to 20% of the patients with clinically diagnosed
neuropathic pain [22,28] and in the study from Spain only
approximately 20% of the patients included had breast cancer and
only 30% of the neuropathic pain was treatment-related, which did
not allow for direct comparisons with our results.
The interrelationship between neuropathic pain and sleep is
complex and far from being completely explained [29]. Experi-
mental studies have shown a development of hyperalgesia and a
decrease of pain threshold with sleep deprivation [30,31], in
accordance with the growing number of epidemiological studies
showing that in addition to neuropathic pain impairing sleep, poor
sleep quality may also exacerbate neuropathic pain, and the two
symptoms may coexist in breast cancer patients as part of a
symptom cluster that could also include fatigue and psychiatric
disorders, namely anxiety and depression [29]. In our study, the fact
that the percentage of patients with neuropathic pain diagnosed
among those with good and poor sleep quality at baseline was
approximately the same argues in favor of neuropathic pain
impairing sleep rather than the inverse relation.
Among the PSQI components, neuropathic pain was more
strongly associated with the daytime dysfunction and sleep dura-
tion specific components. This is consistent with previous studies
using objective sleep measures that showed that patients suffering
from different pain disorders presented lower sleep efficiency and
increased wakefulness [32]. In fact, sleepiness and the decrease of
slowwave sleep are frequently reported as a side-effect of the most
commonly used drugs in neuropathic pain treatment [32] and
could, at least in part, explain these findings. In our study, gaba-
pentin and pregabalinwere the most frequently used drugs to treat
neuropathic pain, which is in accordance with the recommenda-
tions for neuropathic pain pharmacological management of the
European Federation of Neurological Societies Task Force [33].
However, this may have contributed to attenuate the effect of this
neurological condition on global sleep quality, mostly among those
with poor sleep quality at baseline, who were more frequently
treated, as both drugs have consistently demonstrated efficacy in
reducing sleep disturbances associated with neuropathic pain
[34,35]. The use of complementary therapies for pain relief (e.g.
acupuncture) may have also contributed to lessen the effect of
neuropathic pain on sleep quality, but these exposures were not
evaluated in our study.
The major methodological strengths of our study are the pro-
spective design, with a systematic evaluation of sleep quality prior
to treatments, the nearly complete follow-up of patients and the
use of the IASP grading system to classify neuropathic pain. Still,
some limitations need to be addressed. First, the assessment of a
cohort with a large number of participants precluded the use of
objective measures of sleep, obtained through polysomnography or
actigraphy. Nevertheless, the individuals' perception about sleep
has demonstrated to be an important determinant of quality of life
[6,7] and thus should be analyzed in addition to objective mea-
sures, and the PSQI is one of the recommended instruments for the
assessment of sleep or insomnia symptoms [36]. Secondly, we
evaluated essentially women in early stages of disease who un-
derwent surgery, which limits the generalization of our results to
patients with more advanced stages. Third, future studies may
include information regarding other potential confounders of the
relation between neuropathic pain and poor sleep quality,
including preexisting conditions such as back pain or fibromyalgia,
that were not evaluated in the present study. Finally, the use of
sleep medication, expectedly more frequent among those with
poor sleep quality at baseline, may have played a role as a regulator
of pain, decreasing neuropathic pain severity. Also, during the
follow-up period, sleep medication prescription may have beenmore intensive among women diagnosed with neuropathic pain, as
a response to a deleterious effect of this condition on sleep. Both of
the situations may had contributed to the underestimation of the
association found in our analysis. Unfortunately, although we have
self-reported data regarding the frequency of sleep medication use,
evaluated using the PSQI, a finer characterization of these treat-
mentswas not available, precluding a better understanding of these
relations.
In conclusion, we provide evidence of the relation between
cancer treatment-related neuropathic pain and the decrease of
perceived sleep quality during the first year of follow-up, mainly
among those with good sleep quality at baseline. Our findings
highlight the importance of the promotion of sleep hygiene in those
diagnosed with neuropathic pain, and bring attention to those with
higher sleep quality prior to treatments as the target population for
this intervention. Additional research is needed to elucidate the
dynamic interrelationship nature among neuropathic pain and
sleep quality, within those recently treated for breast cancer and in
survivors.
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